FN1 and neoplasm: Following the characterization of EDB-FN expression, tumor contrast enhancement of MT218 was evaluated in mice bearing MDA-MB-231 and Hs578T xenografts before and after intravenous injection of MT218 at 0.1, 0.04, and 0.02 mmol Gd/kg.